NCT07109726 2026-03-23
A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations
Terremoto Biosciences Inc.
Phase 1/2 Recruiting
Terremoto Biosciences Inc.
Ensem Therapeutics
Eli Lilly and Company
ImmunityBio, Inc.